Novobiocin Inhibits Vaccinia Virus Replication by Blocking Virus Assembly  by Sekiguchi, Joann & Shuman, Stewart
VIROLOGY 235, 129–137 (1997)
ARTICLE NO. VY978684
Novobiocin Inhibits Vaccinia Virus Replication by Blocking Virus Assembly
JoAnn Sekiguchi and Stewart Shuman1
Program in Molecular Biology, Sloan-Kettering Institute, New York, New York 10021
Received May 27, 1997; returned to author for revision June 6, 1997; accepted June 16, 1997
Novobiocin inhibits the replication of vaccinia virus in cultured BSC40 cells. All classes of viral proteins were synthesized
during synchronous infection in the presence of drug. The onset of DNA replication was delayed slightly, yet the extent
of DNA replication in the presence of novobiocin was comparable to that of a control infection. A delay in the temporal
transition to late viral protein synthesis was in keeping with the effects on DNA replication. Although the precursor forms
of the major viral structural proteins were synthesized normally at late times, the proteolytic processing of these polypep-
tides was inhibited, which suggested an impediment to virus assembly. Electron microscopy revealed that novobiocin
blocked virus morphogenesis at an early stage. Conversion of the concatameric DNA replication intermediates into hairpin
telomeres occurred in the presence of novobiocin, confirming that telomere resolution was not coupled to virus assembly.
Novobiocin is the latest addition to a class of antipoxviral agents, which includes rifampin and IMCBH, that arrest morpho-
genesis. q 1997 Academic Press
INTRODUCTION beginning to be understood in molecular terms as meth-
ods are developed to arrest morphogenesis at specific
Vaccinia virus replicates within the cytoplasm of mam- steps (for review, see Rodriguez et al., 1997). This has
malian cells, in near-autonomy of the host cell nucleus. been achieved through the use of drugs that inhibit virus
Viral gene expression is regulated in a cascade fashion maturation and via the identification of conditional mu-
(reviewed in Moss, 1996). Early genes are transcribed tants of vaccinia virus that display a morphogenesis phe-
by an RNA synthetic machinery packaged within the in- notype under nonpermissive growth conditions. Viral
fecting virus particle. Disassembly of the virion halts early genes involved in morphogenesis have been identified
mRNA synthesis and liberates the DNA genome, which by various approaches: (i) the isolation of mutant viruses
is then replicated by enzymes encoded by early viral that are resistant to drugs that inhibit assembly and the
genes. Intermediate genes are transcribed after the on- mapping of drug-resistance loci (Baldick and Moss, 1987;
set of DNA replication by the vaccinia RNA polymerase Condit et al., 1991; Meis and Condit, 1991; Schmutz et
plus a new set of accessory transcription factors synthe- al., 1991; Tartaglia et al., 1986); (ii) the physical mapping
sized during the early stage of infection. Among the prod- of mutations that confer a temperature-sensitive block to
ucts of intermediate genes are factors that reprogram virus assembly (Dyster and Niles, 1991; Ericsson et al.,
the RNA polymerase to transcribe the late class of viral 1995; Kane and Shuman, 1993; Wang and Shuman, 1995;
genes. Each stage of virus macromolecular synthesis is Traktman et al., 1995); and (iii) the engineering of condi-
contingent upon proper execution of the preceding phase
tional null mutations in genes known to encode structural
of viral gene expression.
components of the intracellular mature virus particle (Ra-
The assembly of new virus particles commences after
vanello and Hruby, 1994; Rodriguez et al., 1995, 1996,
the onset of late gene expression. Unlike viral gene ex-
1997; Wolffe et al., 1996; Zhang and Moss, 1991, 1992).
pression, which is turned on and off in discrete stages,
Of the many drugs that inhibit vaccinia virus replica-virus assembly is asynchronous and proceeds continu-
tion, two compounds—rifampin and N-1-isonicotinoyl-ously during the late phase of the replicative cycle. For-
N-2-3-methyl-4-chlorobenzoylhydrazine (IMCBH)—spe-mation of the infectious virion and the release of virus
cifically block virus assembly without grossly affectingparticles from the cell have been described at the level
viral nucleic acid metabolism or viral protein synthesis.of electron microscopy (Morgan, 1976; Dales et al., 1978;
Rifampin causes assembly to arrest after the formationSodeik et al., 1993, 1994). These are events of enormous
of abnormal membrane-enclosed structures (rifampinbiochemical and structural complexity that are only just
bodies), which contain viroplasm, but lack the rigid
spherical shape of normal immature particles (Sodeik et
al., 1994). The rifampin bodies appear to lack the spicule1 To whom correspondence and reprint requests should be ad-
dressed. layer characteristic of the normal immature forms. Rifam-
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pin resistance and hypersensitivity are attributable to Sigma, was stored as a 100 mM stock solution in water
and diluted in DMEM prior to each use.point mutations in the D13 gene (Tartaglia et al., 1986;
Baldick and Moss, 1987), which encodes a 65-kDa poly-
Viral protein synthesispeptide. IMCBH inhibits the release of infectious progeny
virus particles from the cell by preventing the wrapping Confluent cell monolayers (9.6-cm2 wells) were in-
of intracellular virions by Golgi membranes (Payne and fected with vaccinia virus at a multiplicity of 10. The inoc-
Kristensson, 1979). IMCBH targets a virus-encoded 37- ula were removed after 30 min and replaced with control
kDa protein component of the Golgi-derived viral enve- medium or medium containing 0.3 or 0.4 mM novobiocin.
lope (Schmutz et al., 1991). At various times postinfection, the medium was removed,
In this paper, we describe the inhibitory effects of the and cells were washed with methionine-free DMEM and
coumarin drug novobiocin on the replication of vaccinia then overlaid with fresh medium containing 30 mCi/ml of
virus in cultured BSC40 cells. The coumarin antibiotics, [35S]methionine (800 Ci/mmol) for 30 min. For cells in-
novobiocin and coumermycin A1, have been extensively fected in the presence of the drug, novobiocin was in-
studied as inhibitors of bacterial DNA gyrase (Maxwell, cluded during the labeling phase. The medium was re-
1993). Coumarins inhibit DNA gyrase by binding to the moved and the cells were lysed in situ by the addition
gyrB subunit and blocking the interaction of the enzyme of 0.5 ml of a solution containing 0.065 M Tris–HCl (pH
with its essential ATP cofactor. Novobiocin and coumer- 6.8), 2% sodium dodecyl sulfate (SDS), 5% b-mercapto-
mycin are quite potent against gyrase, but also inhibit a ethanol, and 10% glycerol. Lysates were stored at 0207.
variety of other enzymes at higher drug concentrations Samples (30-ml aliquots) were heated at 957 for 5 min
(Webb and Jacob, 1988; Fox et al., 1996). Antiviral action and then electrophoresed through a 12.5% polyacryl-
of coumermycin has been reported against herpes sim- amide gel containing 0.1% SDS. Radiolabeled polypep-
plex virus type 1 (HSV1) and it was suggested that the tides were visualized by autoradiographic exposure of
viral DNA polymerase might be the drug target (Palu the dried gel.
et al., 1986). Novobiocin and coumermycin inhibit HSV1
replication in neural cells and also inhibit virus reactiva- Processing of viral structural proteins
tion from trigeminal ganglia (Spivack et al., 1987).
Synchronously infected cells were pulse-labeled forThe inhibitory effects of novobiocin on vaccinia replica-
30 min with [35S]methionine at 12 hr postinfection astion in vivo (Ikeda et al., 1987) have not been examined
described above. The cells were washed twice within any detail. Vaccinia encodes several potential targets
DMEM after the labeling medium was removed and thenfor the coumarin drugs. Of particular interest to us is
either lysed immediately (chase time 0) or overlaid withthe vaccinia virus type I DNA topoisomerase, which is
fresh medium containing unlabeled methionine. Theinhibited by novobiocin and coumermycin in vitro (Fogel-
monolayers were returned to incubate at 377 and thensong and Bauer, 1984; Shaffer and Traktman, 1987; Seki-
lysed in situ after 1, 2, 4, or 8 hr. Aliquots (40 ml) wereguchi et al., 1996a). We have shown that the coumarin
analyzed by SDS–PAGE.drugs bind to the vaccinia topoisomerase and competi-
tively block the DNA-binding site on the enzyme (Seki-
Viral DNA replication
guchi et al., 1996a). The coumarin drugs also inhibit RNA
synthesis in vitro by vaccinia virus particles (Fogelsong Confluent BSC40 cell monolayers (4.0-cm2 wells) were
infected with vaccinia virus at a multiplicity of 10. Theand Bauer, 1984) and by a partially purified transcription
complex isolated from virion extracts (Broyles and Moss, inoculum was removed after 30 min and replaced with
drug-containing medium. Control infections were per-1987). In addition, novobiocin inhibits the vaccinia virus
DNA ligase (Shuman, 1996). We now report that novobio- formed in the absence of drug. Cells were harvested at
2, 4, 8, 12, and 24 hr postinfection and pelleted in acin is indeed an inhibitor of vaccinia replication in vivo
and that the drug appears to block virus assembly at an clinical centrifuge. Cell pellets were resuspended in
phosphate-buffered saline and subjected to freezing andearly stage. Somewhat surprisingly, we find that novobio-
cin had relatively little impact on viral gene expression thawing, followed by sonication. Aliquots of the lysates
were denatured in alkali and applied to a nylon mem-or DNA replication.
brane (Zetaprobe; Bio-Rad) using a vacuum slot-blot ap-
paratus. The abundance of viral DNA sequences wasMATERIALS AND METHODS
assayed by hybridizing to the filter a radiolabeled vac-
Materials
cinia DNA probe synthesized by the nick translation
method from a plasmid DNA template containing theBSC40 cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 5% fetal calf vaccinia genomic HindIII F restriction fragment. Hybrid-
ized probe was detected and quantitated by scanningserum. Vaccinia virus WR was routinely propagated in
BSC40 monolayers at 377. Novobiocin, purchased from the filter with a FUJIX BAS1000 Bio-imaging analyzer.
AID VY 8684 / 6a3f$$$$62 07-22-97 08:27:54 viras AP: VY
131NOVOBIOCIN INHIBITS VACCINIA VIRUS REPLICATION
Resolution of vaccinia telomeres
Confluent BSC40 cell monolayers (9.6-cm2 wells) were
infected with vaccinia virus at a multiplicity of 10. The
inoculum was removed after 30 min. The cells were
rinsed twice with DMEM and then overlaid with DMEM
(control) or DMEM containing novobiocin. Cells were har-
vested at 6, 12, and 24 hr postinfection and pelleted
in a clinical centrifuge. The cells were resuspended in
phosphate-buffered saline and recentrifuged. The
washed cells were resuspended in 50 ml of 0.15 M NaCl,
20 mM Tris–HCl (pH 8.0), 1 mM EDTA and then lysed
by mixing the suspension with 250 ml of 20 mM Tris –
HCl (pH 8.0), 1 mM EDTA, 0.75% SDS. The lysates were
digested with 200 mg of proteinase K for 6 hr at 377. FIG. 1. Novobiocin inhibition of vaccinia virus plaque formation. Con-
The samples were extracted sequentially with phenol, fluent BSC40 monolayers were infected with vaccinia WR (200 PFU/
well). The inoculum was removed after 60 min and the cells were thenphenol:chloroform, and chloroform and then precipitated
overlaid with medium containing novobiocin at the indicated concentra-with ethanol. The nucleic acid was resuspended in 100
tions. Plaque formation was visualized by staining with 0.1% crystal
ml of 10 mM Tris–HCl (pH 8.0), 1 mM EDTA and then violet at 48 hr postinfection.
passed through a 26-gauge needle. The DNA was di-
gested with restriction endonuclease BstEII (50 units,
NEB) for 20 hr at 377. Aliquots of the digests were electro- hr postinfection by staining the monolayers with crystal
phoresed through a 0.8% agarose gel in TAE buffer (40 violet. (Note that addition of drug after removal of the
mM Tris-acetate, 1 mM EDTA). DNA was transferred to inoculum excluded any possibility that the drug might
a Zetaprobe membrane (Bio-Rad) according to the manu- interfere with virus adsorption.) In control cells without
facturer’s protocol. The membrane was hybridized with drug, vaccinia formed well-circumscribed clear plaques
a 32P-labeled telomeric DNA probe prepared by nick visible against a background of intact cells (Fig. 1). Inclu-
translation of plasmid pBD6, which contains a BstEII con- sion of novobiocin at concentrations £0.1 mM had no
catamer junction fragment inserted into pUC13 effect on the number or the size of the plaques (not
(Merchlinsky et al., 1988). The hybridized probe was de- shown). Plaque size was reduced at 0.2 mM novobiocin
tected by autoradiography. (Fig. 1). Microscopic plaques were detected at 0.3 mM
novobiocin. At 0.4 mM drug, there was no macroscopic
Electron microscopy
or microscopic evidence of plaque formation (Fig. 1). The
cell monolayer was unperturbed by exposure to novobio-BSC40 cell monolayers were infected with vaccinia
cin in this concentration range. Toxicity of novobiocin tovirus at an m.o.i. of 10. The inoculum was removed after
uninfected cells (manifested as cell rounding and, at30 min, and the cells were washed twice with medium
higher doses, by dissociation from the plastic surface)and then overlaid with either control medium or medium
was evident at concentrations in excess of 0.6 mM.containing 0.4 mM novobiocin. At 24 hr postinfection,
To test if novobiocin inhibition of plaque formation wascells were dislodged by scraping and then spun in a
reversible, cells were exposed to 0.4 mM novobiocin forclinical centrifuge. The supernatant was removed and
24 hr postinoculation, at which time the drug-containingthe cell pellet placed immediately on ice. Cells were fixed
medium was withdrawn and replaced with drug-freeinitially in 2.5% glutaraldehyde, followed by fixation in 2%
osmium tetroxide. Specimens were dehydrated and then DME and incubated for an additional 24 hr. Although no
embedded in epoxy resin (Polybed 812). Thin sections plaques had formed after 24 hr in the presence of drug,
were stained with uranyl acetate and lead citrate for normal-appearing vaccinia plaques were evident 24 hr
visualization in a Jeol 1200 CX transmission electron mi- after novobiocin was removed (not shown). The number
croscope. of plaques formed after drug removal was similar to the
number seen after 24 hr in a drug-free control. Hence,
the antiviral effect of novobiocin was reversible.RESULTS
Failure to form plaques in the presence of novobiocin
Novobiocin inhibits vaccinia replication in vivo
may result from inhibition of virus replication or an imped-
iment to virus spread. Thus, we examined the effects ofBSC40 cells were infected with vaccinia virus at low
novobiocin under synchronous growth conditions (Fig. 2).multiplicity; the inoculum was removed, and the cells
A typical one-step growth curve was obtained for controlwere overlaid with medium containing novobiocin in the
range 0–0.6 mM. Plaque formation was assessed at 48 infections performed in the absence of drug; infectious
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Effect of novobiocin on viral protein synthesis
The patterns of viral protein synthesis in the presence
or in the absence of drug were analyzed by pulse-label-
ing synchronously infected cells with [35S]methionine
over a 12-hr time course postinfection. Cell lysates were
prepared immediately after the pulse and the profile of
newly synthesized polypeptides was examined by SDS–
PAGE (Fig. 4). The normal temporal pattern of vaccinia
gene expression was seen in the control infections, i.e.,
the appearance of novel early polypeptides (E) at 2–4 hr
postinfection visible against a background of host protein
synthesis, transition to the synthesis of distinctive lateFIG. 2. One-step infection in the presence of novobiocin. Confluent
proteins (L) by 6 hr, and shut-off of host (H) protein syn-BSC40 cell monolayers (4.0-cm2 wells) were infected with vaccinia virus
at a multiplicity of 10. The inoculum was removed after 30 min and thesis, also by 6–8 hr postinfection (Fig. 4). Exposure to
replaced with medium containing 0.3 or 0.4 mM novobiocin. Control 0.3 mM novobiocin had no apparent effect on the timing
infections were performed in the absence of drug. Cells were harvested of viral protein synthesis. At 0.4 mM novobiocin, the tran-
at the indicated times postinfection. Virus yield (log PFU) is plotted as
sition from early to late protein synthesis was delayeda function of time postinfection.
slightly, such that characteristic late polypeptides were
synthesized prominently at 8 hr rather than at 6 hr (Fig.
4). This is consistent with a slight delay in the onset ofprogeny were detected at 12 hr postinfection and contin-
DNA replication in the presence of 0.4 mM novobiocin;ued to accumulate with time. The yield at 36 hr reflected
i.e., late protein synthesis requires prior onset of DNAa burst size of about 50 PFU/cell. Inclusion of 0.3 mM
replication. The results presented thus far show that no-novobiocin postinoculation slowed the rate of viral repli-
vobiocin had no significant effect on viral gene expres-cation and reduced virus yield by a factor of 40 (Fig. 2).
sion. Hence, the basis for inhibition of viral productionAt 0.4 mM novobiocin, there was no detectable produc-
must lie elsewhere.tion of infectious progeny above the residua of the inocu-
lum, i.e., the baseline titer at 1 hr postinfection.
Novobiocin inhibits processing of virion structural
proteins
Effect of novobiocin on vaccinia DNA replication
Two major structural proteins of the virion core —4a
Although the results of the experiment depicted in Fig. and 4b —are encoded by the vaccinia virus A10 and A3
2 showed that novobiocin inhibited vaccinia replication, genes, respectively. Each is synthesized at late times
it remained to be determined which intracellular stage(s) as a precursor polypeptide (p4a or p4b) that is proteolyti-
of the virus life cycle was affected by the drug. Initial cally processed to yield the mature species (VanSlyke
experiments focused on landmark events of viral macro- et al., 1991a,b; Takahashi et al., 1994). The precursor
molecular synthesis in synchronously infected cells. The
extent of DNA replication was assayed by slot-blot hy-
bridization (Rempel et al., 1990). Cell lysates prepared at
various times postinfection in the absence of drug were
immobilized on membranes and probed with a radiola-
beled vaccinia genomic DNA fragment. Scanning of the
hybridized filter revealed low levels of viral DNA at 4 hr,
with obvious amplification of viral sequences by 8 hr that
continued up to 24 hr (Fig. 3). Inclusion of 0.3 and 0.4
mM novobiocin appeared to delay the onset of viral DNA
replication by about 1 hr, as judged from the levels of
viral DNA at 4 hr and by extrapolation of the curves to
the x-axis (Fig. 3). Nonetheless, the rates of viral DNA
accumulation between 4 and 12 hr were essentially unaf-
FIG. 3. Effect of novobiocin on viral DNA replication. The amplificationfected by 0.3–0.4 mM drug (Fig. 3). In this experiment,
of vaccinia DNA as a function of time postinfection was measured bythe yield of viral DNA at 24 hr was reduced by half in
slot-blot hybridization as described under Materials and Methods. The
the presence of 0.4 mM novobiocin. Hence, the complete signal intensity of the hybridized probe (PSL, photostimulatable lumi-
abrogation of virus production by 0.4 mM novobiocin was nescence) was measured by scanning the membrane with a Phos-
phorImager.not the result of drug inhibition of viral DNA replication.
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FIG. 4. Effect of novobiocin on viral protein synthesis. Synchronously infected cells were pulse-labeled for 30 min with [35S]methionine as described
under Materials and Methods. Monolayers were lysed in situ and the labeled polypeptides were analyzed by SDS–PAGE. An autoradiogram of the
gel is shown. The infections were performed in the absence of drug or in the presence of 0.3 or 0.4 mM novobiocin. The times (hr postinfection)
of the pulse labeling are indicated above the lanes. The positions and sizes (in kDa) of prestained molecular weight markers are shown at the left.
Representative vaccinia early (E) and late (L) proteins and a prominent host polypeptide (H) are indicated at the right.
polypeptides p4a and p4b were readily identified in [35S]- provides biochemical evidence that novobiocin affects
virus morphogenesis. This was evaluated by electronmethionine pulse-labeling reactions performed at 12 hr
postinfection and were converted to mature forms 4a microscopy.
and 4b during an 8-hr chase in the presence of unla-
beled methionine (Fig. 5, control). p4a and p4b were Electron microscopy
synthesized during virus infection in the presence of 0.4
mM novobiocin, but there was no apparent processing The mature vaccinia virion evolves in stages from mi-
croscopically well-characterized immature forms. Theto 4a and 4b, even after 8 hr of chase (Fig. 5, 0.4 mM
Novo). Because almost any mutation or drug treatment earliest of these are crescent-shaped spicule-coated vi-
ral membranes, which are observed either free in thethat blocks virus assembly also affects processing of
the virion structural precursors, the pulse– chase result cytoplasm or associated with centers of electron-dense
FIG. 5. Defective processing of virion structural proteins in the presence of novobiocin. Virus infections were performed in the absence of drug
or in the presence of 0.3 or 0.4 mM novobiocin. Cells were pulse-labeled for 30 min with [35S]methionine at 12 hr postinfection and then either
lysed in situ immediately after labeling (lane 0) or chased for the times indicated (hr) in medium containing unlabeled methionine. Radiolabeled
polypeptides were analyzed by SDS–PAGE. An autoradiograph of the gel is shown. The labeled polypeptides corresponding to the structural protein
precursors p4a and p4b are indicated by filled circles at right; their processed products 4a and 4b are designated by the open circles.
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FIG. 6. Novobiocin inhibits the assembly of progeny virions. Virus-infected cells were harvested at 24 hr postinfection and visualized by electron
microscopy.
viroplasm. Spherical immature viral particles are formed brane. The blots were then hybridized with radiolabeled
upon closure of the membrane around the granular mate- vaccinia DNA containing terminal genomic sequences.
rial. These spherical immature particles develop into ma- BstEII digestion of concatemer replication intermediates
ture brick-shaped virions, clusters of which were evident yields a 2.6-kb fragment, whereas mature hairpin te-
in the cytoplasm of cells infected with virus in the ab- lomeres yield a 1.3-kb fragment (Fig. 7). An 11-kb re-
sence of drug (Fig. 6, Control). Mature progeny virions striction fragment flanking the telomeres also hybridizes
were rare in cells that were exposed to novobiocin post- to the probe and provides an internal standard for the
adsorption (Fig. 6, 0.4 mM novobiocin). Spherical imma- extent of viral DNA replication (Fig. 7). In control virus-
ture particles and membrane crescents were rare as infected cells, most of the telomeric sequences were
well. Thus, the inhibition of vaccinia replication could be resolved into the mature form at each time point ana-
attributed to a global defect in virus assembly. lyzed. This attests to the high efficiency with which con-
catemers are resolved in vivo and is in agreement with
Resolution of vaccinia telomeres the results of Merchlinsky and Moss (1989).
We again observed a lag in the onset of DNA replica-The ends of the 192-kb linear vaccinia genome consist
tion in the presence of 0.3 and 0.4 mM novobiocin, re-of hairpin telomeres that link the complementary strands
flected in a decreased hybridization signal at the 6 hrinto one uninterrupted polynucleotide chain. The te-
time point (Fig. 7). Also, at 6 hr in the presence of novobio-lomeres are 104-nt incompletely base-paired structures
that exist in two forms (‘‘flip’’ and ‘‘flop’’) that are inverted
and complementary (Baroudy et al., 1982). The telomere
structure is formed by resolution of concatemeric DNA
replication intermediates into unit-length DNA mole-
cules. The concatemer junctions, which are flanked by
large inverted repeats, are converted to mature te-
lomeres by a conservative DNA strand exchange reac-
tion (Merchlinsky and Moss, 1986; DeLange et al., 1986;
Merchlinsky, 1990). Although telomere resolution re-
quires the expression of late viral genes (Merchlinsky
and Moss, 1989), virtually nothing is known about the
identity of specific viral proteins involved in telomere res-
olution. We analyzed the effects of novobiocin on te-
lomere resolution using the Southern-blotting technique
described by Merchlinsky and Moss (1989). DNA was
FIG. 7. Telomere resolution. A Southern blot of DNA from virus-isolated from infected cells at 6, 12, and 24 hr postinfec-
infected cells was hybridized with a telomeric probe. An autoradiogram
tion and then digested with restriction endonuclease of the blot is shown. The positions of the 2.6-kb concatemer junction
BstEII. The digests were electrophoresed through an fragment and the 1.3-kb mature telomere fragment are indicated on
the left.agarose gel and DNA was transferred to a nylon mem-
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cin, a substantial fraction of telomeric DNA was in the our experiments entailed addition of drug 30 min after
virus inoculation, we might have overlooked a potentialform of concatemer junctions (Fig. 7). We surmise that
this is caused by the delayed onset of late protein synthe- drug effect on viral early gene expression. We addressed
this point by pretreating the cell monolayers for 4 hrsis, an event that is essential for telomere resolution. At
12 and 24 hr postinfection in the presence of novobiocin, with 0.4 mM novobiocin prior to virus inoculation and
maintaining the drug during and after adsorption. Wethe extent of DNA amplification was virtually equivalent
to that of control cells and the normal high efficiency found that pretreatment had no effect on the pattern of
early and late viral protein synthesis compared to postin-of telomere resolution was reestablished (Fig. 7). We
conclude that novobiocin inhibits morphogenesis, but oculation drug treatment. We conclude that 0.4 mM no-
vobiocin does not target virus adsorption or virus earlyhas no direct effect on telomere resolution. This agrees
with the earlier report that rifampin inhibition of virus gene expression in vivo.
How does novobiocin inhibit morphogenesis at anassembly had no impact on telomere resolution
(Merchlinsky and Moss, 1989). early stage? The membrane crescents are believed to
derive from the intermediate compartment—a mem-
brane cisterna situated in the vesicular trafficking path-DISCUSSION
way between the endoplasmic reticulum and the Golgi
stacks (Sodeik et al., 1993). The intermediate compart-The studies presented above indicate that novobiocin
inhibition of vaccinia virus replication was caused by a ment hypothesis invokes some molecular ‘‘cement’’ that
bridges the two membranes and obliterates the lumen.block at an early stage of virus morphogenesis. This
effect appeared to be direct, insofar as the drug caused This could be accomplished either by a single viral pro-
tein that transits through both membranes or by two sep-no significant inhibition of viral gene expression or DNA
replication. The novobiocin phenotype was similar to arate proteins that make contact across the lumen. There
must be some asymmetry of the fused membrane struc-those elicited by conditional mutations in viral genes F10
or A17, the products of which are implicated in the initia- ture that facilitates the acquisition of curvature, e.g., a
specific ligand on the concave face of the crescentstion steps of viral membrane formation (Wang and Shu-
man, 1995; Traktman et al., 1995; Rodriguez et al., 1995; which interacts with some other partner. The vaccinia
21-kDa A17 protein, which localizes initially to the roughWolffe et al., 1996). Novobiocin appears to act prior to
the events targeted by rifampin (acquisition of membrane endoplasmic reticulum and is a component of viral mem-
brane crescents, has emerged as a plausible candidaterigidity) and IMCBH (Golgi wrapping of intracellular ma-
ture virus), the two other drugs that specifically block for initiating membrane reorganization (Rodriguez et al.,
1996). A 15-kDa phosphoprotein encoded by the A14vaccinia assembly.
The assembly defect was unexpected, given earlier gene is also found in the intermediate compartment and
viral membranes (Rodriguez et al., 1997). Conceivably,findings that the coumarin drugs inhibit a number of
vaccinia enzymes involved in DNA and RNA transac- the F10 protein kinase, which is essential for membrane
formation (Wang and Shuman, 1995), may be responsibletions. For example, novobiocin inhibits vaccinia topo-
isomerase, an enzyme that is essential for virus replica- for phosphorylating A14 and/or other proteins involved
in membranogenesis. In this context, any number of spe-tion (Shuman et al., 1989). The precise role of the topo-
isomerase during the vaccinia life cycle remains unclear. cific models can be invoked for novobiocin inhibition of
assembly. These include: (i) novobiocin interacts withWe have suggested that topoisomerase functions in te-
lomere maturation by resolving Holliday recombination one of the viral membrane proteins (e.g., A17 or A14) and
specifically blocks either its localization or its function;intermediates (Sekiguchi et al., 1996b). It is obvious from
the present study that novobiocin does not affect te- (ii) the drug inhibits the F10 protein kinase; and (iii) no-
vobiocin elicits a nonspecific defect in membrane traf-lomere resolution, at least not when added at 0.3– 0.4
mM concentration in the medium. Note that this concen- ficking. The first two models envision a specific viral gene
product as the target of novobiocin action. The classicaltration of novobiocin elicits a 50% inhibition of topoisom-
erase activity in vitro (Sekiguchi et al., 1996a). Hence, genetic approach to defining the viral target of drug ac-
tion would be to isolate a drug-resistant virus mutanttopoisomerase may be only marginally affected in our in
vivo experiments. We doubt that topoisomerase is the in (Condit and Niles, 1990). The third model posits a cellular
target; this scenario is less amenable to genetics.vivo target of novobiocin’s antipoxvirus activity.
Similar arguments pertain to the relationship of the in It is worth considering the potential utility of coumarin
drugs as anti-poxviral therapeutic agents. Althoughvivo drug phenotype to the in vitro inhibition of vaccinia
virus RNA polymerase by 0.5–1 mM novobiocin (Fogel- smallpox is no longer extant, the emergence of mol-
luscum contagiosum virus as a common and disfiguringsong and Bauer, 1984; Broyles and Moss, 1987). Note
that because early mRNAs are synthesized immediately skin infection in AIDS patients illustrates the need for
drugs active against the poxviruses (Gottlieb andafter virus penetration into the cytoplasm, and because
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and sequence of the concatemer junction from vaccinia virus replica-Myskowski, 1994). Topical therapy of molluscum contagi-
tive DNA. J. Mol. Biol. 199, 399–413.osum, i.e., local application of drug to infected skin, es-
Merchlinsky, M., and Moss, B. (1986). Resolution of linear minichromo-
chews systemic toxicity of drugs like the coumarins, somes with hairpin ends from circular plasmids containing vaccinia
which may have pleiotrophic effects on cellular functions virus concatamer junctions. Cell 45, 879–884.
Merchlinsky, M., and Moss, B. (1989). Resolution of vaccinia virus DNAat high doses.
concatamer junctions requires late gene expression. J. Virol. 63,
1595–1603.
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